Pharmaceuticals Australia

Australia Cancer Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Cancer Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $80.8 Mn Placeholder estimate
Estimate 2025 $91.1 Mn 1.1% of the global market
Projected 2034 $267.1 Mn 193.3% Adds $176.0 Mn over 9 forecast years
CAGR 2025–2034 12.7% Faster than 65% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.06% of the global market.
  • In APAC, the largest is China at $754.7 Mn.
  • Fastest growing: India at 14.4% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$176.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Vaccines Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $80.8 Mn — —
2025 (base) $91.1 Mn +$10.3 Mn —
2026 (forecast) $102.6 Mn +$11.6 Mn +12.7%
2027 (forecast) $115.7 Mn +$13.0 Mn +27%
2028 (forecast) $130.4 Mn +$14.7 Mn +43.1%
2029 (forecast) $146.9 Mn +$16.6 Mn +61.3%
2030 (forecast) $165.6 Mn +$18.7 Mn +81.8%
2031 (forecast) $186.6 Mn +$21.0 Mn +104.9%
2032 (forecast) $210.3 Mn +$23.7 Mn +130.9%
2033 (forecast) $237.0 Mn +$26.7 Mn +160.3%
2034 (forecast) $267.1 Mn +$30.1 Mn +193.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Cancer Vaccines Market Analysis at a glance
Market size, 2025$91.1 Mn placeholder estimate
Forecast, 2034$267.1 Mn placeholder estimate
Growth (CAGR), 2025–203412.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication and end user (see all)
Key playersModerna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC, Gritstone bio (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials11 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Cancer Vaccines Market Analysis Executive Summary

Cancer vaccines train the immune system to recognise and attack cancer, including personalised mRNA vaccines and preventive vaccines.

Key segments of the cancer Vaccines market include type (Personalized Neoantigen Vaccines, Preventive Vaccines and Dendritic Cell Vaccines) and indication (Melanoma, Lung Cancer and Prostate Cancer).

Bar chart: Australia Cancer Vaccines market size, 2024–2034, placeholder estimates. $80.8 Mn in 2024, $91.1 Mn in 2025 and $267.1 Mn in 2034, 12.7% CAGR.
Australia Cancer Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Cancer Vaccines Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Vaccines market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Vaccines market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Vaccines Market in Australia

The cancer Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Vaccines Market in Australia

Cancer Vaccines in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 11 studies on Cancer Vaccines that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Vaccines right now, from free public sources.

Clinical trials

11 active trials in Australia

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Merck & Co., Inc. 8 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanghai Bovax Biotechnology Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  3. ModernaTX, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  4. OSE Immunotherapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Shanghai Zerun Biotechnology Co.,Ltd 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Vaccines in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Vaccines market in Australia?
Placeholder estimate: about $91.1 Mn in 2025, rising to about $267.1 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Vaccines market in Australia growing?
Placeholder estimate: about 12.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Vaccines market report cover?
The report splits the market by type (Personalized Neoantigen Vaccines, Preventive Vaccines, Dendritic Cell Vaccines, Viral Vector Vaccines), indication (Melanoma, Lung Cancer, Prostate Cancer, Cervical Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Vaccines market?
Key players include Moderna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC and Gritstone bio.
What is driving the Cancer Vaccines market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Vaccines in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Cancer Vaccines are running in Australia?
11 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Cancer Vaccines?
PubMed lists 2,635 papers on Cancer Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on oncology and vaccines

See the topic